Lexicon Pharmaceuticals vs Sunshine Biopharma
LXRX and SBFM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and SBFM compare
Lexicon Pharmaceuticals is the larger company, worth 1025 times as much as Sunshine Biopharma ($810M against $790K).
Sunshine Biopharma grew revenue faster over the last twelve months (−5.2% versus −45.6% for Lexicon Pharmaceuticals).
Sunshine Biopharma keeps more of each dollar of sales as profit, with a net margin of −17.5% compared with −162% at Lexicon Pharmaceuticals.
Sunshine Biopharma scores higher on the StockData Score (12 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | SBFM |
|---|---|---|
| Size and price | ||
| Market cap | $810M | $790K |
| Share price | $1.82 | $2.84 |
| Change, 1 year | 16.7% | −99.2% |
| Change, 5 years | −63.3% | −76.3% |
| Beta (5Y) | 1.76 | – |
| Employees | 81 | 50 |
| StockData Score | ||
| Total score | 5 | 12 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 21.0× | 0.0× (better) |
| P/B | 4.9× | 0.0× (better) |
| Fair value | $0.882 | $213.99 |
| Margin of safety | −106% | 98.7% (better) |
| Growth | ||
| Revenue growth (TTM) | −45.6% | −5.2% (better) |
| Revenue growth, 5Y average | 15.7% | 248% (better) |
| Profitability | ||
| Gross margin | 98.9% (better) | 30.4% |
| Operating margin | −147% | −17.2% (better) |
| Net margin | −162% | −17.5% (better) |
| Return on equity | −43.9% | −23.4% (better) |
| Return on invested capital | −140% | −33.3% (better) |
| Financial health | ||
| Debt / equity | 0.32 (better) | 0.00 |
| Current ratio | 10.63 (better) | 6.47 |
| Altman Z-score | −5.49 | −1.80 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −8.7% | – |
| Shareholder yield | −8.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 81.9% | 28.9% |
| Held by insiders | – | 24.5% |
| Insider net buying, 12 months | $2.8M | – |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- SBFM stock overview
- SBFM income statement
- SBFM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.